Quick member survey – improving PV communication

Communications / 14 April 2022

If you have a spare couple of minutes, your input can help UMC continue to improve our pharmacovigilance communication methods.


As some of Uppsala Reports’ readers may have already seen, UMC recently created an animated explainer video to raise awareness of vigiGroup – UMC’s cluster analysis method developed to identify groups of ADR reports with similar adverse events. The purpose of the video, which was shared widely on social media, was to offer an alternative way to communicate the methodology put forward in UMC’s academic paper “Consensus clustering for case series identification and adverse event profiles in pharmacovigilance.”

At UMC, we are always looking to develop, evolve, and refine how we communicate the science of pharmacovigilance, and this project provides us with an excellent opportunity to do just that. We would like to assess the effectiveness of animated explainer videos to convey complex scientific methods by getting feedback from you, our readers, in the form of a short survey. It will only take a few minutes of your time and you don’t need a PV or scientific background to take part.

The survey, along with the explainer video, is available here:

Take the survey

 

Thanks for you help.

Matthew Barwick
Communications officer & video producer, UMC

You may also like


Patient voices in pharmacovigilance takes centre stage at ISoP Bali 2023

The most recent ISoP event saw hundreds of experts gather to explore the latest innovations and challenges facing pharmacovigilance, with a special focus on patient perspectives.

Communications / 16 January 2024

Patient safety set to gain from new partnership between CDISC and UMC

The partnership seeks to improve the interoperability of CDISC standards and WHODrug Global for more effective sharing and use of medicinal product safety data.

Communications / 20 February 2024

When drugs damage the liver– New podcast out now

The liver, responsible for drug metabolism in the body, is also most at risk of damage due to medicines. Unravel the complexities of DILI and its impact on medication safety.

Communications / 05 February 2024

Our website uses cookies

Cookies are small text files held on your computer. They allow us to give you the best browsing experience possible and mean that we can understand how you use our site. Some cookies have already been set. You can delete and block cookies but parts of our site won't work without them. By using our website you accept our use of cookies.

Find out more